drugset / Trial / NCT04319705
Anti-viral Effects of Azithromycin in Patients With Asthma and COPD
Phase 4
Unknown
100 enrolled
Bispebjerg Hospital
Herlev and Gentofte Hospital · collabLund University · collabUniversity of Copenhagen · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to investigate the anti-viral effects of low-dose AZM treatment in patients with asthma and COPD with an exacerbation history. The investigators expect that long-term treatment with low dose AZM modulates the immune response to viral infections, with an increased interferon release, in patients with asthma and COPD with an exacerbation history. In addition, the investigators expect a decrease in inflammatory cells and mediators, and changes in bacteria, measured in samples from the lungs. Half of the participants will receive azithromycin on top of their regular asthma/COPD treatment, while the other half will receive placebo on top of their regular asthma/COPD treatment.
Timeline
- Start
- 2020-03-02
- Primary completion
- 2022-03-31
- Completion
- 2022-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azithromycin | Small molecule | 500 mg | Oral |